SCHEMBL3514654

SCHEMBL3514654

CN(C)C=CC(=O)C(F)(F)F

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.60
CYP2C19 P33261 3/20 0.49
KDM4E B2RXH2 3/20 0.45
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
THRB P10828 1/20 0.41
ALDH1A1 P00352 3/20 0.40
CYP1A2 P05177 2/20 0.39
GAA P10253 2/20 0.39
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
RECQL P46063 2/20 0.38
HTT P42858 1/20 0.35
RAB9A P51151 1/20 0.35
HPGD P15428 1/20 0.35
ALOX12 P18054 1/20 0.35
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3514649 1.00 TDP1 (0.60) TDP1CYP2C19KDM4EMEN1KMT2A
SCHEMBL5676812 0.88 TDP1 (0.48) TDP1CYP2C19KDM4EMEN1KMT2A
SCHEMBL5676823 0.88 TDP1 (0.48) TDP1CYP2C19KDM4EMEN1KMT2A
SCHEMBL5676816 0.88 TDP1 (0.48) TDP1CYP2C19KDM4EMEN1KMT2A
SCHEMBL6977513 0.77 TDP1 (0.62) TDP1CYP2C19KDM4EMEN1KMT2A
SCHEMBL678566 0.77 TDP1 (0.62) TDP1CYP2C19KDM4EMEN1KMT2A
SCHEMBL13221154 0.77 TDP1 (0.62) TDP1CYP2C19KDM4EKMT2ALMNA
SCHEMBL19182708 0.75 TDP1 (1.00) TDP1CYP2C19KDM4EKMT2ALMNA
SCHEMBL19183375 0.75 TDP1 (1.00) TDP1CYP2C19KDM4EKMT2ALMNA
SCHEMBL20721986 0.71 TDP1 (0.56) TDP1CYP2C19KDM4EKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720055-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF Arcus Biosciences, Inc. (US) 2026-04-08 EP disclosed
US-20250011318-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2025-01-09 US disclosed
WO-2024243502-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2024-11-28 WO disclosed
US-20230242532-A1 TETRACYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF NEUSCO BIOTECH LIMITED (CN) 2023-08-03 US disclosed
EP-4039687-A1 TETRACYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF Neusco Biotech Limited (CN) 2022-08-10 EP disclosed
US-20210040043-A1 HALOGEN SUBSTITUTED DIKETONES, PYRAZOLE COMPOUNDS AND PROCESSES FOR THE MANUFACTURE OF PYRAZOLE COMPOUNDS SOLVAY (BE) 2021-02-11 US disclosed
US-10829456-B2 Halogen substituted diketones, pyrazole compounds and processes for the manufacture of pyrazole compounds SOLVAY SA (BE) 2020-11-10 US disclosed
EP-3605699-A1 NEW COMPONENTS FOR ELECTROLYTE COMPOSITIONS SOLVAY SA (BE) 2020-02-05 EP disclosed
US-20190031616-A1 HALOGEN SUBSTITUTED DIKETONES, PYRAZOLE COMPOUNDS AND PROCESSES FOR THE MANUFACTURE OF PYRAZOLE COMPOUNDS SOLVAY SA (BE) 2019-01-31 US disclosed
US-20100324073-A1 Pyrazolo [1,5-A] Pyrimidine Compounds WYETH LLC (US) 2010-12-23 US disclosed
EP-2235020-A1 PYRAZOLO [1,5-A] PYRIMIDINE COMPOUNDS Wyeth LLC (US) 2010-10-06 EP disclosed
WO-2009086129-A1 PYRAZOLO [1,5-A] PYRIMIDINE COMPOUNDS WYETH (US) 2009-07-09 WO disclosed
US-7329753-B2 Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors SCHERING AG (DE) 2008-02-12 US disclosed
US-20060229333-A1 Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2006-10-12 US disclosed
US-7109212-B2 Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors SCHERING AG (DE) 2006-09-19 US disclosed
US-20050165050-A1 Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2005-07-28 US disclosed
US-20050020564-A1 Pyrazole-amides and sulfonamides as sodium channel modulators ABBOTT LABORATORIES 2005-01-27 US disclosed
US-20040220170-A1 Pyrazole-amides and sulfonamides as sodium channel modulators ABBOTT LABORATORIES 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324073-A1 Pyrazolo [1,5-A] Pyrimidine Compounds NR1H2, NR1H3, NR1H4 TDP1 2035/4885CYP2C19 227/4885KDM4E 2850/4885
US-20210040043-A1 HALOGEN SUBSTITUTED DIKETONES, PYRAZOLE COMPOUNDS AND PROCESSES FOR THE MANUFACTURE OF PYRAZOLE COMPOUNDS CYP3A4, PDXK, CYP3A43 TDP1 3497/4885CYP2C19 12/4885KDM4E 1505/4885
US-10829456-B2 Halogen substituted diketones, pyrazole compounds and processes for the manufacture of pyrazole compounds CYP3A4, PDXK, CYP3A43 TDP1 3497/4885CYP2C19 12/4885KDM4E 1505/4885
US-20190031616-A1 HALOGEN SUBSTITUTED DIKETONES, PYRAZOLE COMPOUNDS AND PROCESSES FOR THE MANUFACTURE OF PYRAZOLE COMPOUNDS CYP3A4, PDXK, CYP3A43 TDP1 3497/4885CYP2C19 12/4885KDM4E 1505/4885
US-20060229333-A1 Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors NFKBIA, IL1B, IRF3 TDP1 3228/4885CYP2C19 379/4885KDM4E 3072/4885
US-20050020564-A1 Pyrazole-amides and sulfonamides as sodium channel modulators SCN3A, KCNN3, TRPV3 TDP1 3626/4885CYP2C19 3099/4885KDM4E 3210/4885
US-20050165050-A1 Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors NFKBIA, IL1B, IRF3 TDP1 3228/4885CYP2C19 379/4885KDM4E 3072/4885
US-20040220170-A1 Pyrazole-amides and sulfonamides as sodium channel modulators SCN3A, KCNN3, TRPV3 TDP1 3626/4885CYP2C19 3099/4885KDM4E 3210/4885
US-20230242532-A1 TETRACYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF PLA2G1B, PLA2G5, PLA2G7 TDP1 308/4885CYP2C19 2784/4885KDM4E 4433/4885
US-20250011318-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF CBLB, CBL, CBLC TDP1 1881/4885CYP2C19 4104/4885KDM4E 1545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.